TY  - JOUR
AU  - Belvís, Robert
AU  - Irimia, Pablo
AU  - Pozo-Rosich, Patricia
AU  - González-Oria, Carmen
AU  - Cano, Antonio
AU  - Viguera, Javier
AU  - Sánchez, Belén
AU  - Molina, Francisco
AU  - Beltrán, Isabel
AU  - Oterino, Agustín
AU  - Cuadrado, Elisa
AU  - Gómez-Camello, Angel
AU  - Alberte-Woodward, Miguel
AU  - Jurado, Carmen
AU  - Oms, Teresa
AU  - Ezpeleta, David
AU  - de Terán, Javier Díaz
AU  - Morollón, Noemí
AU  - Latorre, Germán
AU  - Torres-Ferrús, Marta
AU  - Alpuente, Alicia
AU  - Lamas, Raquel
AU  - Toledano, Carlos
AU  - Leira, Rogelio
AU  - Santos, Sonia
AU  - Del Río, Margarita Sánchez
PY  - 2021
DO  - 10.1186/s10194-021-01267-x
UR  - http://hdl.handle.net/10668/18210
T2  - The journal of headache and pain
AB  - Erenumab was approved in Europe for migraine prevention in patients with ≥ 4 monthly migraine days (MMDs). In Spain, Novartis started a personalized managed access program, which allowed free access to erenumab before official reimbursement. The...
LA  - en
KW  - Erenumab
KW  - Migraine
KW  - Monoclonal antibody
KW  - Preventive treatment
KW  - Registry
KW  - Antibodies, Monoclonal, Humanized
KW  - Europe
KW  - Female
KW  - Humans
KW  - Middle Aged
KW  - Migraine Disorders
KW  - Registries
KW  - Spain
TI  - MAB-MIG: registry of the spanish neurological society of erenumab for migraine prevention.
TY  - research article
VL  - 22
ER  -